Gilead sees 'positive' data on coronavirus treatment remdesivir trial
Gilead coronavirus treatment shows positive results
Gilead’s trial of coronavirus treatment Remdesivir is showing positive data and driving up the markets. Raymond James Biotech Research Director Dr. Steven Seedhouse with more.
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.
Continue Reading Below
Gilead Sciences on Wednesday touted "positive data" coming from a study of the use of its drug remdesivir as a coronavirus treatment.
CORONAVIRUS PATIENT STUDY RAISES QUESTIONS ABOUT WHETHER TEMPERATURE CHECKS WORK
In the study, 62 percent of patients who received the drug within 10 days of symptoms were discharged from the hospital, compared with 49 percent of those treated late.
“These study results complement data from the placebo-controlled study of remdesivir conducted by the National Institute for Allergy and Infectious Diseases and help to determine the optimal duration of treatment with remdesivir," Gilead Sciences Chief Medical Officer Dr. Merdad Parsey said in a statement.